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Introduction
In less than a decade, immune checkpoint inhibitors 
(ICIs) have become standard of care in the treatment of 
advanced non-small cell lung cancer (NSCLC), either in 
first line (alone in selected patients or in the near future 
in combination in others) or beyond. Pembrolizumab, 
a programmed death-1 (PD-1) inhibitor is registered 
in first line for advanced NSCLC patients, without an 
activating epidermal growth factor receptor (EGFR) 
mutation or anaplastic lymphoma kinase (ALK) aberration, 
but with a programmed death-ligand 1 (PD-L1) tumor 
proportion score (TPS) of ≥50%. It is also registered in 
second line for those with a PD-L1 TPS of ≥1%. This 
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registration is based on the results of the KEYNOTE-024 
(pembrolizumab versus platinum-doublet chemotherapy) 
and KEYNOTE-010 (pembrolizumab versus docetaxel) 
trials, respectively (1,2). In second line, nivolumab, another 
PD-1 inhibitor, is also registered regardless of PD-L1 
expression based on the results of the CheckMate 017 
trial (squamous NSCLC, nivolumab versus docetaxel) and 
CheckMate 057 trial (non-squamous NSCLC, nivolumab 
versus docetaxel) (3,4). Atezolizumab, a PD-L1 inhibitor, 
is also registered for second line treatment regardless 
of PD-L1 expression based on the results of the OAK 
trial (atezolizumab versus docetaxel) (5). Although PD-
L1 expression is a predictive biomarker for outcome on 
PD-(L)1 inhibitor, it is not a perfect biomarker as even 
in the patients with a PD-L1 expression of ≥50% the 
overall response rate (ORR) is only 44.8% (1). Moreover, 
PD-L1 expression level did not adequately enrich the first 
line population to demonstrate that single agent nivolumab 
is superior to platinum-doublet chemotherapy. In the 
CheckMate 026 trial, untreated advanced NSCLC with a 
PD-L1 TPS of ≥1% were randomized between nivolumab 
and platinum-doublet chemotherapy, primary endpoint was 
PFS among patients with a PD-L1 expression level of ≥5%. 
The trial was negative for its primary endpoint, but also in 
the exploratory subgroup analysis of patients with a PD-L1 
TPS of ≥50% no benefit of nivolumab over chemotherapy 
was seen (6). Furthermore, in trials with combination ICI 
such as the phase II CheckMate 568 [nivolumab combined 
with ipilimumab, a cytotoxic T-lymphocyte-associated 
antigen (CTLA-4) antibody], the randomized phase III 
CheckMate 227 trial (nivolumab plus ipilimumab versus 
chemotherapy or nivolumab monotherapy) and the phase 
Ib trial of durvalumab (anti-PD-L1) and tremelimumab 
(anti-CTLA4), ICI benefit was seen irrespective of PD-
L1 expression level (7-9). Last, in the randomized phase 
III KEYNOTE-189 trial (first line platinum doublet 
chemotherapy with pembrolizumab or placebo in non-
squamous NSCLC) and the randomized phase III 
IMPOWER 150 trial (carboplatin/paclitaxel combined 
with either atezolizumab, atezolizumab/bevacizumab or 
bevacizumab) a benefit of adding PD-(L)1 inhibition to 
chemotherapy was seen regardless of PD-L1 expression 
level, although benefit was highest in those with high PD-
L1 status (10,11). As even in these combination therapy 
trials a significant proportion of patient did not respond 
(ORR ranged from 45.3% to 64.0%) and not all responding 
patients had long-term benefit (7,10,11), other biomarkers 
are needed that are better able to predict beneficial 
outcome of ICI treatment. Until now, besides PD-L1, 
only mismatch repair (MMR) deficiency has been Food 
and Drug Administration (FDA) approved as a predictive 
biomarker (12). Moreover, there are several issues on PD-
L1 testing such as the use of different antibodies, different 
platforms and different cut-offs for positivity that are 
extensively reviewed elsewhere (13).
One of the new promising biomarkers is tumor 
mutational burden (TMB). In this comprehensive review, 
we discuss the rationale to use TMB as a predictive 
biomarker, the analysis methods and the clinical utility of 
TMB in NSCLC patients treated with ICI.
TMB definition and TMB assessment methods
TMB has first been determined with whole exome 
sequencing (WES). Currently, WES seems to be less 
feasible in daily practice as it is costly, time consuming, 
labour intensive and needs large sequencing capacity (14,15). 
TMB can also be determined through hybrid-capture based 
targeted next generation sequencing [large next-generation 
sequencing (NGS) panel—NGS laboratory developed test 
(LDT)], for example using the FoundationOne® assay (first 
version of F1 LDT test) or the FoundationOne CDxTM 
assay (F1 CDxTM, current FoundationOne assay) (16-18). 
In contrast to WES, large panel NGS is increasingly used 
in daily practice, usually with a limited number of genes. 
TMB is defined as the total number of somatic mutations in 
the tumor exome (17). There are different ways to estimate 
the total number of somatic mutations. The parameters 
are the type of mutations, the minimal allelic frequency 
and the strategy of excluding germline variants. In WES, 
the germline variants are oftenly excluded with a WES 
applied to healthy tissue. The results are expressed as a total 
number of mutations. The NGS FoundationOne assays 
define TMB as the total number of synonymous and non-
synonymous mutations present at ≥5% allele frequency 
(after filtering) in the sequenced tumor genome. Results 
are expressed as mut/Mb (18,19). Multiple platforms exist 
for large NGS panel analyses. Some assays have correlated 
the TMB result from WES to a large NGS panel. For 
example, the F1 LDT assay with a region of interest around 
1.1 megabase (Mb) and 315 genes has been correlated to 
WES (16), with a Spearman’s r=0.9, and positive and 
negative agreements between methods both 86% (20). 
Furthermore, TMB values of the F1 LDT and the 
F1 CDxTM assay (coverage 0.8 Mb, 324 genes) correlate 
well (19). However, below 0.5 Mb the variance in measurements 
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towards WES results increases significantly (16). Depending 
on the study in which a FoundationOne® assay (F1 LDT 
or F1 CDxTM) is used, high TMB is defined as ≥9.9 to 
20 mut/Mb (7,9,21-24). A good correlation for TMB 
determined by WES and large panel NGS was also found 
for other assays. For example, another study compared 
WES to a 500-gene targeted NGS panel including various 
cancer-relevant genes. Both approaches correlated linearly 
(regression equation =0.96), and the NGS panel achieved 
a sensitivity of >90% and a specificity of >85% compared to 
WES when classifying tumors as TMB high. Cutoff for TMB 
high values with NGS was 15 mut/Mb in this assay (25). The 
Memorial Sloan Kettering-Integrated Mutation Profiling 
of Actionable Cancer Targets (MSK-IMPACT) is another 
example with a panel of 341 (version 1) to 468 genes 
(version 3). TMB determined by the MSK-IMPACT assays 
(versions 1–3 used in this study) was highly correlated to 
WES (Spearman ρ=0.86; P<0.001), patients were considered 
TMB high when they had >7.4 mut/Mb (14). There are no 
published studies comparing the performance between each 
of the different large panel NGS but harmonization efforts 
are ongoing (26,27). 
As an alternative to tissue, a recent method of TMB 
evaluation is exploring TMB directly in circulating tumoral 
DNA (ctDNA) from blood/plasma (bTMB). In one study, 
bTMB was determined using a 394-gene panel and was 
compared to tissue TMB (FoundationOne® assay, not 
mentioned whether this was F1 LDT or F1 CDxTM) and 
to the FoundationACT (FACT) dedicated to ctDNA 
assay (including only 62 genes). A total of 259 patients 
were evaluable for both bTMB and tissue TMB. Overall 
agreement and positive percent agreement (PPA) were 
81.5% and 63.6% respectively when using the 394-gene 
panel for bTMB. However, when the FACT assay was 
compared to tissue TMB, PPA dropped to 17%, probably 
due to the low number of genes included in the panel. 
However, the performance on variant detection was similar 
when overlapping allele regions were compared: 93% of 
variants were detected in both assays (28).
Causes of high TMB
There are multiple causes for somatic mutations in cancer 
such as defective DNA repair, intrinsic small errors in the 
DNA replication machinery, enzymatic modification of 
DNA and exogenous exposures (29). When a cell divides, 
multiple errors occur, mainly at the sites of microsatellites: 
most of these errors are corrected during “proofreading” 
(30,31) .  The MMR genes  correct  the  remaining 
errors (32). Mutations in these damage repair genes can 
occur as germline mutation and as somatic mutations, 
both result in hypermutated tumors with a microsatellite 
instability-high (MSI-high) phenotype (33). Some 
colorectal cancers (e.g., the ones occurring in relation to 
the Lynch syndrome) are associated with a defect DNA 
MMR (34). Examples of exogenous exposures causing 
somatic mutations are tobacco smoking in lung cancer and 
ultraviolet light in skin cancers (35). 
Variance of TMB number is high between and within 
tumor types (36-39). Tumors that are often found to 
have a high TMB are melanoma, NSCLC, bladder, 
oesophagus, colon, head and neck, gastric and endometrial 
cancers (38,40,41). A high TMB has been associated with 
smoking or a molecular smoking signature in lung cancer 
and head and neck cancer (38,40,41). Another dominant 
signature associated with a high TMB in lung cancer is 
the apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC) signature (38,40). Stage of 
disease (I/II versus III/IV) is not correlated to TMB (41). 
Several other mutations such as POLD1, POLE, MSH2, 
POLR2A, KEAP1, PAPPA2, PXDNL, RYR1, SCN8A and 
SLIT3 have been associated with a high TMB, however 
with the exception of KEAP1 mutations they seem rare in 
NSCLC (16,42,43). 
Tobacco smoke carcinogens cause direct DNA damage 
and increase cancer risk by increasing the somatic 
mutation load as compared to non-smokers for whom the 
presence of a driver oncogene will be sufficient for the 
tumorigenesis (44,45). 
Most driver mutations are found in non-smoking 
NSCLC patients and these patients have a lower TMB. 
In a large dataset including 1,775 EGFR mutated, 489 
ALK/ROS1 rearranged, 286 MET exon 14 mutated, 493 
v-Raf murine sarcoma viral oncogene homolog B (BRAF) 
mutated and 3,155 kirsten rat sarcoma viral oncogen (KRAS) 
mutated NSCLC patients, mean TMB and proportion of 
patients with a TMB of >10 or 20 mut/Mb was significantly 
lower for EGFR, ALK/ROS1 and MET exon 14 mutated 
patients compared to KRAS mutated patients. Mean TMB 
ranged from 3.1 to 6.2 mut/Mb for these patients compared 
to 10.3 mut/Mb for KRAS mutated patients. Mean TMB 
was similar for BRAF mutated compared to KRAS mutated 
patients (9.7 versus 10.3 mut/Mb), and TMB of these 
patient groups was comparable to all adenocarcinoma 
patients (mean TMB 9.1 mut/Mb). Squamous cell 
carcinoma patients had a slightly higher mean TMB (11.3). 
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TMB was evaluated through a large NGS panel (24). 
Updated results (using instead of mean values the median 
values, median being the correct measure to use in a skewed 
population such as the TMB samples) including over 15,000 
analyzed lung cancer cases confirmed these results, except 
for the lower median TMB in BRAF mutated patients 
(3.8 mut/Mb) (46). 
A smaller series of 83 patients evaluated for TMB 
through the FoundationOne® assay (not mentioned 
whether F1 LDT or F1 CDxTM) confirmed the lower 
TMB in EGFR and ALK positive patients but found also 
a lower TMB in KRAS mutated patients when EGFR, 
ALK and KRAS mutated patients were compared to driver 
mutation negative patients (47). The lower TMB of 
EGFR mutated tumors compared to wildtype tumors was 
confirmed in another series of 108 resected early stage 
lung adenocarcinomas (48). In lung adenocarcinoma, it was 
found that number of mutations or neoantigens was higher 
in tumors with high PD-L1 and high CD8A/cytolytic 
activity (CYT) compared to tumors with low PD-L1 and 
low CD8A/CYT, the latter being an immune ignorant 
TME (49). In contrast to driver mutated NSCLCs with 
mostly a low TMB, pulmonary sarcomatoid tumors were 
found to have a high TMB in one retrospective series: 41% 
of the 122 included sarcomatoid tumors had a TMB of 
>10 mut/Mb (in a large panel NGS) and 18% had a 
TMB of >20 mut/Mb in one study (50). Large-cell 
neuroendocrine carcinoma of the lung (LCNEC) has a 
TMB that seems similar to that reported of adenocarcinoma 
patients when compared to the adenocarcinoma TMB 
in the series of Spigel et al. although in the latter mean 
was provided instead of median (median 9.9 versus mean 
9.1 mut/Mb) (24,51).
Relevance of TMB in immunotherapy treated 
patients
The goal of ICI treatment is that the patient’s immune 
system is stimulated to reject the tumor and by doing this 
induces a long-lasting tumor response. There are several 
steps necessary to achieve this. Among them, the tumor 
should express neoantigens (tumour-specific, mutated 
peptides presented on the surface of cancer cells) that 
should be adequately processed and presented by the major 
histocompatibility complex (MHC) and afterwards these 
neoantigens should be recognized by T-cells as non-self to 
achieve an adequate anti-tumor T-cell response (52-55). 
The higher the number of neoantigens in a certain tumor, 
the higher the chance that a T-cell response is initiated to 
one or more of these neoantigens. It has been shown that 
the number of candidates neoantigens per tumor correlates 
well with TMB (56,57).
TMB and ICI outcomes in advanced NSCLC trials
Several studies using samples of patients included in clinical 
trials as well as retrospective series reported ICI outcome 
for NSCLC patients in relation to TMB. These are 
described below and summarized in Table 1.
Trial data
Pembrolizumab
One of the first series demonstrating a superior clinical 
efficacy of ICI in NSCLC patients with high TMB 
was published in 2016.  TMB was evaluated with 
WES, 2 independent cohorts of patients treated with 
pembrolizumab were sequenced (N=16 and N=18). A 
median of 200 nonsynonymous mutations was identified 
(range, 11–1,192). High TMB was defined as TMB above 
the median burden of the cohort (209 in discovery, 200 in 
validation cohort). In the discovery cohort 73% of patients 
with high TMB had durable clinical benefit compared to 
only 13% of those with low TMB (P=0.04). ORR was 63% 
versus 0% in those with high versus low TMB, respectively 
(P=0.03), progression free survival (PFS) was 14.5 versus 
3.7 months, respectively [hazard ratio (HR) 0.19; 95% CI: 
0.05–0.70; P=0.01]. Similar results were obtained in the 
validation cohort (56). 
Atezolizumab
In a retrospective pooled analysis of the FIR and BIRCH 
trials (both single arm first line and beyond atezolizumab 
trials, including patients selected for PD-L1 positivity) 
a PFS benefit and a trend to an OS benefit was found in 
TMB high patients from the FIR and BIRCH trial. In total, 
417 out of 797 patients were included in the biomarker 
evaluable population (BEP). TMB was determined in tissue 
with the F1 LDT panel. Patients with a TMB above the 
median (9.9 mut/Mb) had a PFS HR of 0.49 compared to 
those with a TMB below the median in first line (total of 
87 patients in BEP) and a PFS HR of 0.64 in second line 
and beyond (total of 330 patients in BEP). HR for OS was 
0.71 and 0.86, respectively [both not significant (NS)]. With 
a TMB high cutoff at the 75% quantile (16.2 mut/Mb), 
HR for PFS in first and second line/beyond was 0.7 (NS) 
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and 0.55, respectively. HR for OS was 0.35 and 0.77 (NS) 
respectively. Comparable results were found for the patients 
in the POPLAR trial (second line and beyond atezolizumab 
versus docetaxel, no PD-L1 selection). In the BEP for this 
trial, a total of 92 out of 287 patients were included. Median 
PFS was 7.29 months for atezolizumab and 2.83 months 
for docetaxel for patients with a TMB above the median 
(HR 0.49; 95% CI: 0.25–0.93). Median PFS was 8.48 and 
2.83 months respectively when a TMB high cutoff at the 
75% quantile was used (HR 0.49; 95% CI: 0.19–1.3). 
Median OS for atezolizumab versus docetaxel was 16.23 
versus 8.31 months in the TMB > median population 
(HR 0.48; 95% CI: 0.23–1.04) and not reached versus 
12.16 months in the TMB >75% quantile population (HR 
0.50; 95% CI: 0.15–1.67). In the pooled analysis, TMB 
was weakly correlated with PD-L1 expression but not with 
tumor infiltrating lymphocytes (TIL). The highest ORR 
was found in the patient population with high TMB and 
PD-L1 expression (ORR just below 40%) (21). 
As is clear from the limited number of BEP patients in 
the atezolizumab trials, obtaining enough tissue for large 
panel NGS or WES is challenging. As described above, 
TMB can also be evaluated in blood (bTMB) and this 
was evaluated in an exploratory analysis of the OAK and 
POPLAR trials (794 out of 1,137 patients were evaluable). 
To determine the bTMB, 394 genes from plasma cell-
free DNA were interrogated for single nucleotide variants 
(SNVs) and a score was based on the number of high-
confidence SNVs identified. bTMB did not correlate 
with PD-L1, but improved PFS and OS were seen with 
atezolizumab compared to docetaxel for patients with a 
bTMB of ≥10 in both the OAK and POPLAR trial [PFS 
HR 0.73 and 0.68, respectively; overall survival (OS) HR 
0.69 and 0.59, respectively] (58). 
bTMB is currently prospectively tested in the first 
line single-arm phase II B-F1RST of atezolizumab 
monotherapy for NSCLC patients (NCT 02848651). Co-
primary endpoints are ORR and PFS in the bTMB negative 
and positive subgroups. Arm C of the phase II/III B-FAST 
trial (NCT03178552) evaluates atezolizumab monotherapy 
versus platinum-doublet chemotherapy in advanced 
NSCLC patients. Primary endpoint is PFS. 
Nivolumab ± ipilimumab
The first TMB data for nivolumab came from the 
CheckMate 026 trial (6). In this first line randomised phase 
III trial, stage IV/recurring NSCLC patients with a PD-
L1 expression of ≥1% were randomised to nivolumab 
monotherapy or platinum-doublet chemotherapy. The trial 
was negative for its primary endpoint (PFS in the group 
of patients with a PD-L1 expression of ≥5%). However, 
in an exploratory analysis, TMB determined with WES 
correlated with outcomes. Low TMB was defined as 
0–100 mutations, median as 100–242 mutations and high as 
243 or more. A total of 312 out of 541 (58%) randomized 
patients were evaluable for TMB and a slightly higher 
percentage of patients with a high TMB was found in the 
chemotherapy group compared to the nivolumab group 
(39% versus 30%). ORR as well as median PFS were higher 
in high TMB patients treated with nivolumab compared 
to high TMB patients treated with chemotherapy. ORR 
was 47% and 28% respectively, median PFS was 9.7 versus 
5.8 months, respectively (HR 0.62; 95% CI: 0.38–1.00). 
Median OS was not significantly different but cross-over 
rate was high (68%). No correlation was found between 
TMB and PD-L1 status, but those with high TMB as well 
as high PD-L1 (≥50%) had, when treated with nivolumab, 
a superior ORR (75%) compared to those with only one of 
the markers defined as high (ORR 32–34%) or when both 
markers were classified as low (ORR 16%) (6). 
Similar results were found in an exploratory analysis of 
arm G the CheckMate-012 study (nivolumab + ipilimumab). 
Totally, 75 of the 197 included patients had sufficient tumor 
tissue and paired blood for WES. ORR, durable clinical 
benefit (DCB) and PFS were significantly higher in those 
with a TMB above the median [158] compared to those 
with a TMB below the median. ORR was 51% versus 13% 
(P=0.0005), DCB was 65% versus 34% (P=0.011), median 
PFS was 17.1 months for those with a high TMB compared 
to 3.7 months for those with a low TMB (HR 0.41; 95% CI: 
0.23–0.73; P=0.0024). PD-L1 expression was not correlated 
to TMB (P=0.804). Patients with high TMB as well as PD-
L1 expression ≥1% had the best ORR and PFS (57). 
In the CheckMate 568 trial, a single-arm phase II 
study of first line nivolumab plus ipilimumab in advanced 
NSCLC, the investigators sought to identify an appropriate 
TMB cut-off to select patients for this first line ICI 
combination. Primary endpoint was ORR, one of the 
secondary endpoints was ORR by TMB. In contrast to the 
Checkmate 026 trial, TMB was determined through large 
panel NGS with the validated F1 CDxTM assay. 288 patients 
were included, and overall ORR was 27%. 98 patients (34%) 
were evaluable for TMB. ORR plateaud with the threshold 
of ≥10 mutations/Mb. ORR was 4% with TMB <5, 10% 
with TMB <10, 44% with TMB ≥10 and 39% with TMB 
≥15 mut/Mb. With receiver operating characteristic (ROC) 
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curves optimal classification performance was found at 10 
mut/Mb. Median PFS (95% CI) was higher in TMB high 
patients [7.1 (3.6–11.3) versus 2.6 (1.5–5.4) months] (9).
The first randomized phase III trial evaluating ICI 
outcome in NSCLC patients predefined in relation to 
TMB was the CheckMate 227 trial (7). In this open label 
trial two separate cohorts of NSCLC patients [one cohort 
with PD-L1 expression of ≥1% (N=1,189), the other 
cohort with PD-L1 expression of <1% (N=550)] were 
randomized to nivolumab plus ipilimumab, platinum-
doublet chemotherapy or nivolumab monotherapy (when 
PD-L1 <1% nivolumab combined with platinum-based 
chemotherapy). The initial primary endpoint was OS 
with nivolumab or nivolumab plus ipilimumab versus 
chemotherapy on the basis of PD-L1 expression (≥1% 
versus <1%). When the results of the CheckMate 568 trial 
became available, the trial was amended to add a co-primary 
endpoint of PFS with nivolumab plus ipilimumab versus 
chemotherapy in a patient population on the basis of TMB 
(i.e., patients were not tested for TMB at baseline and 
patients were not stratified for TMB). Cutoff for high TMB 
was 10 mut/Mb based on the results of the CheckMate 568 
trial (TMB again determined by the F1 CDxTM assay) (56). 
One of the secondary endpoints was PFS with nivolumab 
versus chemotherapy among patients with a TMB of 
≥13 mut/Mb and a PD-L1 level of ≥1%. A total of 1,004 
of 1,739 (57.7%) included patients (across all treatment 
groups) were evaluable for TMB. In total, 330 of 583 
(56.6%) nivolumab + ipilimumab treated patients and 
349 of 583 (59.9%) chemotherapy treated patients were 
evaluable for TMB. A total of 139 of 330 (41.1%) and 160 
of 349 (45.8%) patients were TMB high in the nivolumab + 
ipilimumab and chemotherapy arms, respectively. Baseline 
characteristics (including PD-L1) were well balanced 
between these TMB high groups. Median PFS was 
significantly higher for patients with a high TMB treated 
with nivolumab plus ipilimumab compared to these treated 
with chemotherapy and was 7.2 (95% CI: 5.5–13.2) versus 
5.5 (95% CI: 4.4–5.8) months (HR 0.58; 95% CI: 0.41–0.81; 
P<0.001). One-year PFS rate was 42.6% versus 13.2% 
respectively, and ORR was 45.3% versus 26.9% respectively. 
After adjusting for baseline PD-L1, sex, tumor type and 
performance status a comparable HR for PFS was found 
(HR 0.57; 95% CI: 0.40–0.80; P<0.001). In contrast, for the 
subgroup of patients with a low TMB, no PFS benefit was 
found for nivolumab plus ipilimumab versus chemotherapy. 
Median PFS was not significantly different and was 3.2 
(95% CI: 2.7–4.3) and 5.5 (95% CI: 4.3–5.6) months, 
respectively (HR 1.07; 95% CI: 0.84–1.35). Interestingly, 
and in contrast to the CheckMate 026 trial, PFS was not 
superior for nivolumab versus chemotherapy in the TMB 
≥13 mut/Mb and PD-L1 level of ≥1% (HR 0.95; 95% CI: 
0.61–1.48; P=0.78) (7). 
Retrospective data from daily practice
Anti-PD(L)1 therapy
In an analysis of 64 NSCLC patients treated with 
nivolumab, pembrolizumab or atezolizumab, a high TMB 
(FoundationOne® assay (not mentioned whether F1 LDT 
or F1 CDxTM), TMB high: ≥15 mut/Mb) was associated 
with a longer duration of therapy: median was 64 versus 
17 weeks (HR 0.396; 95% CI: 0.190–0.825; P=0.010). 
Moreover MSI-high status correlated strongly with 
TMB (24).
Nivolumab
A numerically higher median OS for high TMB NSCLC 
patients treated with nivolumab was found in a small study 
(N=36): median OS (95% CI) was not reached for TMB 
high (≥20 mut/Mb), 10.3 (4.8–15.7) for intermediate TMB 
(6–19 mut/Mb) and 12.4 (7.1–17.1) months (P=0.211). 
Interestingly, a clinical score (iSEND) based on gender, 
performance status, neutrophil-to-lymphocyte ratio (NLR) 
and deltaNLR correlated significantly with OS. Median 
OS (95% CI) was 15.7 (10.8–20.6), 10.3 (4.8–15.7) and 3.7 
(0–7.8) months for iSEND good, intermediate and poor 
groups, respectively (P<0.001). TMB and iSEND were not 
combined to one predictive score (59).
In a series of 444 NSCLC patients treated with 
n ivolumab,  h igh TMB (determined through the 
FoundationOne® (not mentioned whether F1 LDT or F1 
CDxTM) assay, TMB high defined as >20 mut/Mb), patients 
with a high TMB had a longer duration of nivolumab 
therapy (7.5 versus 4.6 months, P=0.001) as well as a longer 
median OS (not reached versus 10 months, P<0.01). In this 
series, PD-L1 status (available for 282 patients) was not 
associated with outcome (23).
In another large series (1,619 samples from the 
FoundationCORE database and 2,139 samples from the 
Flatiron Health Analytic Database) of NSCLC patients 
treated with IC with available TMB [FoundationOne® 
assay (not mentioned whether F1 LDT or F1 CDxTM)] 
and PD-L1 status, TMB and PD-L1 correlated weakly. 
Median TMB was 8.1 mut/Mb and 14.5% had a high TMB 
(defined as ≥20 mut/Mb). PD-L1 status was not associated 
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with duration of therapy but high TBM predicted for 
longer duration of therapy (P=0.001). Interestingly, STK11 
mutations correlated with a high TMB/low-PD-L1 status 
and in a preliminary analysis an inferior outcome on ICI. 
BRAF mutations were correlated with a longer duration of 
therapy irrespective of TMB (22).
The use of TMB determined by a large NGS panel 
(MSK-IMPACT assay) has also been evaluated in 240 
patients treated with anti-PD-(L)1 or anti-PD-(L)1 plus 
anti-CTLA4 combination therapy. 186 (78%) of the treated 
patients were treated outside of a clinical trial. Totally, 29% 
of the patients had DCB and TMB was significantly higher 
in those with DCB compared to those without (median 
8.5 versus 6.6 SNVs/Mb, P=0.0062). DCB was 38.6% vs. 
25.1% in those with a TMB above versus below the 50th 
percentile (P<0.001). PFS HR was 1.38 (P=0.024). TMB 
was also evaluated in a non-ICI, chemotherapy treated 
cohort of NSCLC patients: an inverse relationship between 
TMB and survival was identified (14). PD-L1 expression 
level was also significantly correlated with PFS (HR 0.526; 
P=0.011 for PD-L1 ≥1% versus 0%) but not with TMB. 
Patients with high TMB and PD-L1 positivity (≥1%) had 
the highest rate of DCB (50%) (14). 
Drawbacks of TMB 
Determining TMB becomes increasingly feasible with the 
availability of NGS technology. However, the determination 
of TMB on tissue raises several limitations in term of 
sample consumption and timing of the results. For example, 
for the commercially available F1 CDxTM test, a tumor 
block or 10 unstained tumor slides cut at 4–5 microns 
thickness are preferred with an optimum of 25 mm2 surface 
area and at least 20% (preferred 30%) of tumor nuclei. In 
2018, turnaround time is approximately two weeks, and 
cost is between 2,500 and 5,000 US dollars although it is 
expected that price will decrease with time (18,19,60). 
Secondly, the attrition rate due to sample quality and 
quantity could be higher than current molecular testing. 
The percentage of TMB evaluable patients enrolled in 
clinical trials is lower than that for PD-L1. For example, in 
the CheckMate 568 trial, 88% of patients were evaluable 
for PD-L1 but only 34% were evaluable for TMB 
(F1 CDxTM) (9).
Furthermore, TMB testing is not standardized for the 
different assays used and the definition of high TMB varies 
across studies from ≥7.4 to 20 mut/Mb when measured 
with a large NGS panel (7,9,14,21-24,58,59). As already 
mentioned, harmonization efforts are ongoing (26,27), but 
our opinion is that more prospective clinical trials will be 
needed to correctly determine the threshold and validate 
the clinical utilization of the TMB result. 
Besides quantity and quality of the tissue, time, costs 
and defining the optimal cutoff there are drawbacks of 
measuring TMB as not only total TMB influences outcome 
on ICI. For example, when measuring TMB from a 
single sample, both clonal and subclonal neoantigens are 
counted in the TMB. Clonal neoantigens are present in all 
tumor cells while subclonal neoantigens are only present 
in a subset of tumor cells. In a series of 31 tumors from 
NSCLC patients treated with pembrolizumab it was shown 
that especially those with a high TMB as well as a low 
neoantigen subclonal fraction (defined as <5% subclonal) 
had the most durable clinical benefit with pembrolizumab. 
The authors also demonstrated that T-cells only recognized 
clonal neoantigens and not subclonal neoantigens. This is 
important as chemotherapy seems to enhance TMB mainly 
through the increase of subclonal neoantigens. Even when 
T-cells are generated against these subclonal antigens, 
these T-cells will not be able to control all tumor cells (61). 
Similar results were found in an exploratory analysis of the 
CheckMate 012 trial: clonal predicted neoantigen burden 
was more predictive of improved PFS compared with total 
predicted neoantigen burden (57). 
Not only the load of neoantigens but also the neoantigen 
fitness should also be taken into account (62), This can be 
modelled by not only using information on the frequency 
of the clone but also using amplitude of MHC presentation 
(using relative MHC affinity of wild-type and mutant 
peptide) and T-cell recognition probability (62).
Other factors influencing immunotherapy 
outcome
Besides PD-L1 status and TMB, outcome on ICI can be 
influenced by several factors. An exhaustive coverage of 
biomarkers and other factors that influence outcome on 
ICI is outside of the scope of this review. Some examples 
are summarized here. It has been demonstrated that some 
cancer types have a better outcome with ICI treatment than 
would be expected from the TMB and for other tumors 
outcome is worse (17). Other factors such as viral antigen 
presentation on tumors (e.g., Merkel-cell carcinoma) may 
also result in a favourable ORR despite a lower TMB (63). 
Several oncogenic pathways can also have an impact on 
evasion of antitumor response, as was reviewed in Spranger 
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et al. (64). In summary, defective critical steps in antitumour 
T-cell priming might result in a poor outcome despite 
high TMB. For example, functional dendritic cells are 
necessary for cross-presenting tumor neoantigens through 
the MHC class I pathway. Moreover, there are a certain 
number of gain-of-function alterations such as WNT-beta-
catenin signalling or gain of MYC function that result in 
reduced T-cell recruitment and reduced T-cell activation 
and infiltration, respectively. Loss-of-function alterations 
such as LKB1 (STK11) mutations, PTEN loss, and TP53 loss 
can result in decreased T-cell infiltration, reduced T-cell 
priming and decreased T-cell infiltration, respectively. 
Other aberrations in oncogenic pathways, such as mutations 
in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are 
associated with reduced T-cell infiltration while STAT3 
signalling can decrease expression of pro-inflammatory 
cytokines (57,64). It has been shown that TILs represent 
both a predictive and a prognostic biomarker (65,66). 
Furthermore, gene expression profiling performed in 
longitudinal tumor biopsies showed dynamic changes in 
multiple genes after the initiation of PD-1 therapy. These 
immune signatures could also be a complementary solution 
to guide treatment decisions. Targeted gene expression 
panels quantify the specific RNA expression profiles from 
formalin-fixed paraffin embedded (FFPE) biopsy. The 
quantification of the RNA expression will comprehensively 
delineate an inflamed tumor microenvironment. Immune 
expression profiling has the potential to accurately 
determine the inflammatory status of a tumor better than 
the PD-L1 status alone. The correlations between RNAseq 
and those signatures have been explored and seem very 
acceptable (67). Several approaches are proposed with RNA 
extracted from FFPE: a 25-gene interferon-gamma (IFN-γ) 
signature derived from crude extract (EdgeSeq, HTG 
Molecular Diagnostics Tucson, AZ, USA) and 700 genes 
from isolated RNA (NanoString Technologies, Seattle, WA, 
USA). For lung cancer, several trials have used this option: 
for example, the POPLAR trial with atezolumab and the 
T-effector/IFN-γ signature. An OS HR of 0.43 (95% CI: 
0.24–0.77) was found for atezolizumab versus docetaxel in 
the high gene expression level group compared to an OS 
HR of 1.1 (95% CI: 0.68–1.76) for atezolizumab versus 
docetaxel in the low gene expression group (68). 
It is also important to take into account exogenous 
factors such as use of antibiotics and steroids. It has been 
shown in a retrospective study (N=360, of which 239 
NSCLC) that use of antibiotics within 30 days of ICI start is 
associated with a worse outcome compared to patients that 
did not use antibiotics. For NSCLC patients, median PFS 
was 1.9 versus 3.8 months, respectively (HR 1.5; 95% CI: 
1.0–2.2; P=0.03). Median OS was 7.9 versus 24.6 months, 
respectively (HR 4.4; 95% CI: 2.6–7.7; P<0.01). Use of 
antibiotics retained its significance for OS in multivariate 
analysis (69). An imbalance in gut microbiota has also been 
associated with poor outcomes on ICI, and it is suggested 
that this might be caused by use of antibiotics (70).
Baseline steroid use (prednisolon equivalent of 
≥10 mg/day) was also associated with worse outcome on ICI 
in a retrospective series of 640 NSCLC patients and steroid 
use retained its significance in multivariate analysis [HR for 
PFS 1.31 (P=0.03), HR for OS 1.66 (P<0.001)] (71).
Future: TMB and other biomarkers to guide 
treatment decisions
There are besides PD-L1 and TMB multiple parameters 
associated with ICI outcome (e.g., prognostic scores such as 
LIPI and dNLR, TILs, T-effector/IFN-γ signature, general 
immune fitness, soluble inhibitors, tumor metabolism, 
microbiome), and as such it would be interesting to 
combine several parameters (16,52,66,68,72). 
Challenge when combining multiple biomarkers is 
the increasing number of subgroups that is created. For 
example, with two biomarkers there are already four 
subgroups and this doubles to eight when there are three 
biomarkers combined. It then becomes increasingly difficult 
to define cutoffs and interdependence. In reports of clinical 
trials, only PD-L1 and TMB were combined. 
However, obtaining enough tissue to perform all analysis 
necessary to make a treatment decision (define histological 
subtype, test for molecular drivers, PD-L1 and TMB) 
can be difficult. Furthermore, most predictive biomarkers 
are expensive to perform in daily routine. Exceptions 
are the predictive scores using laboratory values already 
determined in routine clinical care as the LIPI score which 
uses only pretreatment neutrophils, lymphocytes and 
LDH (72). Now, the performance of all those scores should 
be evaluated and compared with PD-L1 or TMB testing.
Conclusions
Anti-PD(L)1 therapy has become standard of care for 
NSCLC, and some of the combination strategies with 
chemotherapy (or anti-CTLA4 therapy) are likely to become 
standard of care in the near future for certain subgroups 
of patients. With all of these possible treatment options, 
657Translational Lung Cancer Research, Vol 7, No 6 December 2018
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2018;7(6):647-660tlcr.amegroups.com
biomarkers are needed to identify which subgroup of 
patients is likely to benefit the most from a certain therapy. 
Although not perfect, a high PD-L1 expression level can aid 
in selecting the right patient population for monotherapy 
pembrolizumab. TMB is an interesting biomarker, however 
assays and definition for high TMB should be standardized 
and it is challenging to obtain an adequate amount of 
tissue. Importantly, high TMB predicted for improved 
PFS with nivolumab plus ipilimumab but OS data of the 
CheckMate 227 are still immature and data for nivolumab 
monotherapy versus chemotherapy are conflicting. When 
assays are standardized and an OS benefit is shown, TMB 
in combination with PD-L1 expression level could help in 
defining subgroups of patients that will likely benefit from 
monotherapy or combination strategies. 
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